Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ocaliva PBC Uptake May Be Slow, But Builds Capital For NASH

Executive Summary

Whether initially gradual or immediately strong, the uptake by physicians of Intercept Pharmaceuticals Inc.'s Ocaliva (obeticholic acid), which was priced at $69,350 per year, will ultimately mean money in the bank for the company, providing the firm the capital it will need to fund the much more lucrative opportunity: NASH, or nonalcoholic steatohepatitis.

You may also be interested in...



Shire's Ornskov Maps Out Future Prospects Post- Baxalta Merger

Shire's Danish chief executive says completing the Baxalta merger will greatly boost the group's exposure to longer acting orphan drugs, bring critical mass and de-risk its current asset mix with new portfolio products; a view widely shared by investors and analysts.

Ocaliva OK'd; Will NASH Success, Acquisition Be Next For Intercept?

As expected, Intercept Pharmaceuticals Inc. was granted an accelerated approval for Ocaliva (obeticholic acid) as a treatment for primary biliary cholangitis. But the drug's potential in the much more lucrative indication of nonalcoholic steatohepatitis may be what piques the interests of larger pharmaceutical companies for a possible acquisition of the New York-based biotech.

Positive Panel, But What's Ahead For Intercept's Ocaliva?

After the FDA's glowing review on paper and even more so at the meeting of the agency's Gastrointestinal Drugs Advisory Committee, it was highly likely the panel would back a speedy approval of Intercept Pharmaceuticals Inc.'s Ocaliva (obeticholic acid) as a treatment for primary biliary cholangitis (PBC), a rare and potentially fatal liver disease.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC065313

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel